A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.

Currently, two prophylactic human papillomavirus (HPV) vaccines targeting HPV 16 and 18 have been shown to be highly efficacious for preventing precursor lesions although the effectiveness of these vaccines in real-world clinical settings must still be determined. Toward this end, an ongoing statewide surveillance program was established in New Mexico to assess all aspects of cervical cancer preventive care. Given that the reduction in cervical cancer incidence is expected to take several decades to manifest, a systematic population-based measurement of HPV type-specific prevalence employing an age- and cytology-stratified sample of 47,617 women attending for cervical screening was conducted prior to widespread HPV vaccination. A well-validated polymerase chain reaction (PCR) method for 37 HPV genotypes was used to test liquid-based cytology specimens. The prevalence for any of the 37 HPV types was 27.3% overall with a maximum of 52% at age of 20 years followed by a rapid decline at older ages. The HPV 16 prevalences in women aged ≤ 20 years, 21-29 years or ≥ 30 years were 9.6, 6.5 and 1.8%, respectively. The combined prevalences of HPV 16 and 18 in these age groups were 12.0, 8.3 and 2.4%, respectively. HPV 16 and/or HPV 18 were detected in 54.5% of high-grade squamous intraepithelial (cytologic) lesions (HSIL) and in 25.0% of those with low-grade SIL (LSIL). These baseline data enable estimates of maximum HPV vaccine impact across time and provide critical reference measurements important to assessing clinical benefits and potential harms of HPV vaccination including increases in nonvaccine HPV types (i.e., type replacement).

Serum Sex Hormones, IGF-1, and IGFBP3 Exert a Sexually Dimorphic Effect on Lean Body Mass in Aging.

BACKGROUND: Endogenous and exogenous sex hormones affect changes in body composition during aging via independent and dependent effects on the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis and associated binding proteins (BP). METHODS: Fasting serum IGF-1, IGFBP3, testosterone, estrone, and sex hormone binding globulin were analyzed in 48 women on hormone replacement (HRT) (unopposed oral estrogen, HRT+, 74.0 +/- 6 years), 135 women not on HRT (HRT-, 77.3 +/- 7 years), and 128 healthy men (men, ). Total lean body mass (LBM) and total fat were measured by dual energy X-ray absorptiometry. RESULTS: Total LBM decreased with age in all groups (p = .05). LBM was greater, and IGF-1, IGFBP3, and testosterone were lower in HRT+ versus HRT- women (p = .02, p = .01, p = .04, and, respectively). LBM in men was positively related to IGF-1 (p = .02) and testosterone (p < .01), whereas LBM was associated with IGFBP3 (p = .04) and total fat (p < .001) in female HRT+ and total fat (p < .01) in HRT- women. IGF-1 decreased with age in men and HRT- women (p < .01) but did not decrease in HRT+ women. Total fat significantly decreased across age (p < .05). Controlling for age and HRT, the rate of decrease in fat was slower in men versus women (p = .02). IGFBP3 decreased in all groups across age (p < .01), and the ratio of IGF-1 to IGFBP3 decreased faster in men compared to HRT+ and HRT- women (p = .02). CONCLUSIONS: Our data indicate divergent influences of sex steroids, IGF-1, and IGFBP3 on age-related changes in LBM in healthy elderly men and women.

Serum leptin levels, bone mineral density and osteoblast alkaline phosphatase activity in elderly men and women.

Although primarily secreted by adipose cells, leptin, a polypeptide hormone that influences body weight, satiety and lipid metabolism, and its receptor are also expressed in human osteoblasts. Leptin plays a role in the central, hypothalamic modulation of bone formation, as well as locally within the skeleton by enhancing differentiation of bone marrow stroma into osteoblasts and inhibiting its differentiation into osteoclasts and adipocytes. The purpose of this investigation was to compare serum leptin values in 100 postmenopausal women (age 62-97) and 31 men (age 72-92) to bone mineral density (BMD) measurements made by dual X-ray absorptiometry and additionally to biochemical markers of bone resorption and formation, including crosslinked collagen N-telopeptides (NTx), aminoterminal extension procollagen propeptides (PINP) and bone-specific alkaline phosphatase (bAP). The circulating level of leptin directly correlated with body mass index (BMI) (r=0.61-0.78, P<0.001) and was modestly, but significantly and positively associated with bAP activity (r=0.24-0.33, P<0.01) in the sera of men and women after adjustment for BMD, age and BMI. The association of circulating leptin levels with bAP, a specific marker of osteoblast activity suggests that leptin levels influence osteoblast activity in vivo in elderly women and men.